EverPoint Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

EverPoint Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.83M	Sell	5,000 -45,000	-90%	-$17.1M	0.03%	328
2016 Q3	$20.1M	Buy	50,000 +35,260	+239%	+$14.1M	0.36%	74
2016 Q2	$5.15M	Buy	+14,740	New	+$5.68M	0.1%	223
2014 Q4	–	Sell	-30,000	Closed	-$10.8M	–	529
2014 Q3	$10.8M	Sell	30,000 -30,000	-50%	-$10.1M	0.25%	131
2014 Q2	$16.9M	Buy	+60,000	New	+$17.8M	0.35%	69

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

EverPoint Asset Management's REGN Position: Q4 2016 in Review

EverPoint Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 90% in Q4 2016, selling an estimated $17.1M and leaving 5,000 shares worth $1.83M. The position accounts for 0.03% of the portfolio, ranked #328.

EverPoint Asset Management first reported a position in REGN in Q2 2014 and has held it in 5 quarters since. The position peaked at $20.1M in Q3 2016. 577 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

EverPoint Asset Management held 5,000 shares of Regeneron Pharmaceuticals worth $1.83M as of Q4 2016.
EverPoint Asset Management sold 45,000 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $17.1M.
Regeneron Pharmaceuticals made up 0.03% of EverPoint Asset Management's portfolio in Q4 2016, its #328 holding.
EverPoint Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 5 quarters since.
EverPoint Asset Management's Regeneron Pharmaceuticals position peaked at $20.1M in Q3 2016.
577 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.